COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.
Featured Posts
R&D/Pipelines Report 2022: Innovating to turn the tide - The world’s leading COVID-19 vaccine and therapeutic manufacturers continue to develop treatments for the waves of variants as well as life-changing therapies for disease areas outside the world of coronaviruses. The world’s efforts to combat the global pandemic continue to evolve, as does Coronavirus Disease 2019 as variants and subvariants constantly toss volleys of grenades at the battlefront lines.Europe’s first “blank cheque” company focused on acquiring companies that make medicines for the biotech and pharmaceutical industry launched on May 9, with plans to raise 150 million euros.
Severe obesity may weaken the effectiveness of COVID-19 vaccines in those who have never been infected with the coronavirus, according to a small Turkish study. Additionally, South African researchers have found infection with the Omicron variant of the coronavirus can significantly improve the immune system’s ability to protect against other variants, but only in people who have been vaccinated.
Biogen is bolstering the company’s multiple sclerosis pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic MR-004, which is being assessed for the potential treatment of gait deficits in MS.
Additional reports of patients with long COVID who were helped by Pfizer Inc.’s oral antiviral treatment Paxlovid offer fresh impetus for conducting clinical trials to test the medicine for the debilitating condition, U.S. researchers said on May 5.
Cerebras Systems, a pioneer in high performance artificial intelligence (AI) computing, and AbbVie, a global biopharmaceutical company, announced a landmark achievement in AbbVie’s AI work.
The Omicron variant of the SARS-CoV-2 virus is intrinsically as severe as previous variants, unlike assumptions made in previous studies that it was more transmissible but less severe, a large study in the United States found.
Two biologic therapeutic candidates met their primary endpoints in separate Phase III trials: AstraZeneca’s Ultomiris and Argenx’s Vyvgart.
Almost three times as many people have died as a result of COVID-19 as official data show, according to a new World Health Organization (WHO) report, the most comprehensive look at the true global toll of the pandemic so far.
AstraZeneca’s proposed treatment for heart disease delivered positive high-level results from the company’s Phase III DELIVER trial.